Trial Profile
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Ralinepag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Acronyms ADVANCE OUTCOMES 301; ADVANCE-Outcomes
- Sponsors Arena Pharmaceuticals; Pfizer; United Therapeutics Corporation
- 04 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 04 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 01 Nov 2023 According to an Unither Pharmaceuticals Media Release, data from this study will generate in 2025.